Donate to the NCCN Foundation
The oncology reimbursement landscape continues to present ever-evolving challenges for clinicians and others that work with patients with cancer. As a response to these ongoing challenges, help is available through the NCCN Virtual Reimbursement Resource Room.
Select a cancer or supportive care indication or select a reimbursement program below to learn about reimbursement help and services available to you to help your practice mitigate reimbursement challenges.
Download the NCCN Reimbursement Resource App for Smartphones and Tablets
Download the NCCN Virtual Reimbursement Resource Room Guide
Now available for Apple and Android smartphones and tablets! As a response to these ongoing challenges, help is available through the NCCN Reimbursement Resource App; users are able to search for available resources and payment assistance programs.
Information on resources available are listed under three different tabs entitled: Search by Cancer Type or Supportive Care Indication, Search by Drug Name (brand or generic), and Search by Reimbursement or Assistance Program.
A printer-friendly 23 page resource to empower patients with cancer and their caregivers as you help them navigate the challenging reimbursement landscape.
Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (newly-diagnosed therapy-related acute myeloid leukemia (t-AML))
Acute Myeloid Leukemia (with myelodysplasia-related changes (AML-MRC) in adults)
Acute Promyelocytic Leukemia (APL)
Basal Cell Carcinoma
Bladder Cancer
Bone Cancer
Bone Metastases
Breast Cancer
Castrate Resistant Prostate Cancer
Cervical Cancer
Chemotherapy-Induced Nausea and Vomiting (CINV)
Chronic Lymphocytic Leukemia
Chronic Myelogenous Leukemia (CML)
Colon Cancer
Colorectal Cancer
Cutaneous Squamous Cell Carcinoma
Cutaneous T-Cell Lymphoma
Diffuse Large B-cell Lymphoma (DLBCL)
Gastric Cancer
Gastroesophageal Junction Cancer
Glioblastoma
Hairy Cell Leukemia
Head and Neck Cancers
Hepatocellular Carcinoma
High Grade B-cell Lymphoma
Hodgkin's Lymphoma
Kidney Cancer
Mantle Cell Lymphoma
Melanoma
Merkel Cell Carcinoma
Metastatic Breast Cancer
Metastatic Cutaneous Squamous Cell Carcinoma
Metastatic Prostate Cancer
Metastatic Prostate Cancer Travel
Metastatic Urothelial Carcinoma
MSI-H/dMMR Cancers
Multicentric Castleman's Disease
Multiple Myeloma
Mycosis Fungoides/Sezary Syndrome
Myelodysplastic Syndromes
Myelofibrosis
Neuroendocrine Tumors
Neuroendocrine Tumors of Pancreatic Origin
Neutropenia
Non-Hodgkin's Lymphomas
Non-Melanoma Cancers
Non-Small Cell Lung Cancer
Ovarian Cancer
Pancreatic Adenocarcinoma
Peripheral T-Cell Lymphoma
Philadelphia Chromosome Negative Myeloproliferative Neoplasms
Prevention and Treatment of Cancer-Related Infections
Primary Mediastinal Large B-cell Lymphoma
Prostate Cancer
Rectal Cancer
Relapsed or Refractory Large B-cell Lymphoma
Renal Cell Carcinoma
Soft Tissue Sarcoma
Thyroid Cancer
Waldenström's Macroglobulinemia
Abiraterone acetate (ZYTIGA®) --- Janssen CarePath
Acalabrutinib (CALQUENCE®) --- AstraZeneca Access 360™
Ado-trastuzumab emtansine (Kadcyla) --- Genentech Access Solutions
Afatinib (GILOTRIF®) --- Boehringer Ingelheim Solutions Plus™
Apalutamide (ERLEADA®) --- Janssen CarePath
Aprepitant (EMEND® for oral suspension) --- The Merck Access Program
Arsenic Trioxide (Trisenox®) --- Teva Oncology: CORE (Comprehensive Oncology Reimbursement Expertise)
avelumab (BAVENCIO®) --- CoverOne® (EMD Serono and Pfizer)
axicabtagene ciloleucel (YESCARTA™) --- Kite Konnect™, Kite, a Gilead Company
Azacitidine for injection (Vidaza®) --- Celgene Patient Support®
Bendamustine (Treanda®) --- Teva Oncology: CORE (Comprehensive Oncology Reimbursement Expertise)
Bevacizumab (Avastin®) --- Genentech Access Solutions
Capecitabine (Xeloda®) --- Genentech Access Solutions
Cemiplimab-rwlc (LIBTAYO®) --- LIBTAYO Surround™
Daratumumab (DARZALEX®) --- Janssen CarePath
Dasatinib (SPRYCEL®) --- SPRYCEL® (dasatinib) Assist
Daunorubicin and Cytarabine liposome for injection (VYXEOS®) --- Jazz Pharmaceuticals: (VYXEOS Reimbursement Patient Support Program)
Durvalumab (IMFINZI®) --- AstraZeneca Access 360™
Elotuzumab (EMPLICITI™) --- BMS Access Support®
Enasidenib (IDHIFA®) --- Celgene Patient Support®
Enzalutamide capsules (XTANDI) --- XTANDI Support SolutionsSM
Epoetin alfa (PROCRIT®) --- Janssen CarePath
Erlotinib (Tarceva) --- Genentech Access Solutions
Everolimus (Afinitor®) --- Patient Assistance NOW Oncology (PANO) (Novartis Oncology)
Fosaprepitant (EMEND® for injection) --- The Merck Access Program
Fulvestrant (FASLODEX®) --- AstraZeneca Access 360™
Gefitinib (IRESSA®) --- AstraZeneca Access 360™
goserelin acetate implant (Zoladex®) --- TerSera SupportSource
HALAVEN® (eribulin mesylate) injection, for intravenous use. --- Eisai Assistance Program
Ibrutinib (IMBRUVICA®) --- YOU&i™ Support Program
Imatinib (Gleevec®) --- Patient Assistance NOW Oncology (PANO) (Novartis Oncology)
iobenguane I 131 (AZEDRA®) --- Progenics Pharmaceuticals, Inc.
Ipilimumab (YERVOY®) --- BMS Access Support®
Please see Full Prescribing Information for YERVOY®(ipilimumab), including Boxed WARNING regarding immune-mediated adverse reactions.
Lenalidomide (Revlimid®) --- Celgene Patient Support®
Lenvima (Lenvatinib®) --- Eisai Assistance Program
Letrozole (Femara®) --- Patient Assistance NOW Oncology (PANO) (Novartis Oncology)
moxetumomab pasudotox-tdfk (LUMOXITI®) --- AstraZeneca Access 360™ Please click here for full Prescribing Information, including BOXED WARNING.
Neratinib (NERLYNX®)--- Puma Biotechnology, Inc.
Nilotinib (Tasigna®) --- Patient Assistance NOW Oncology (PANO) (Novartis Oncology)
Nivolumab (OPDIVO®) --- BMS Access Support®
Nivolumab (OPDIVO®) + Ipilimumab (YERVOY®) Regimen --- BMS Access Support®
Olaparib (LYNPARZA®) --- AstraZeneca Access 360™
Omacetaxine Mepesuccinate (Synribo®) --- Teva Oncology: CORE (Comprehensive Oncology Reimbursement Expertise)
Oncotype DX® Breast DCIS Score™
Oncotype DX Breast Recurrence Score®
Oncotype DX Genomic Prostate Score®
Oncotype DX® Colon Recurrence Score™
Osimertinib (TAGRISSO®) --- AstraZeneca Access 360™
Paclitaxel protein-bound particles for injectable suspension (albumin-bound) (Abraxane®) --- Celgene Patient Support®
Pembrolizumab (KEYTRUDA®) --- The Merck Access Program
Pemetrexed for injection (Alimta®) --- Lilly PatientOne: Reimbursement & Patient Assistance Programs
Pertuzumab (Perjeta) --- Genentech Access Solutions
Pomalidomide (Pomalyst®) --- Celgene Patient Support®
PumaPatientlynx™ Access and Support Program --- Offered by Puma Biotechnology, Inc.
Ramucirumab (Cyramza®) --- Lilly PatientOne: Reimbursement and Patient Assistance Programs
Rituximab (Rituxan) --- Genentech Access Solutions
Romidepsin for injection (Istodax®) --- Celgene Patient Support®
rolapitant tablets (Varubi®) --- TerSera SupportSource
Ruxolitinib (tablets) (Jakafi®) --- IncyteCARES (Incyte Corporation)
Siltuximab (SYLVANT®) --- Janssen CarePath
Tbo-filgrastim (Granix™) --- Teva Oncology: CORE (Comprehensive Oncology Reimbursement Expertise)
Thalidomide (Thalomid®) --- Celgene Patient Support®
Trabectedin (YONDELIS®) --- Janssen CarePath
Trastuzumab (Herceptin®) --- Genentech Access Solutions
Vemurafenib (Zelboraf) --- Genentech Access Solutions
Vismodegib (Erivedge®) --- Genentech Access Solutions
Zoledronic acid (Zometa®) --- Patient Assistance NOW Oncology (PANO) (Novartis Oncology)
- Your Patients - Your Practice - Your Choice
XTANDI Support Solutions℠ is designed as a single point of contact to help patients and their loved ones understand their coverage and reimbursement options for XTANDI (enzalutamide) capsules. Astellas is firmly committed to ensuring our patients have access to XTANDI, regardless of their financial status. We are here to answer questions about your insurance coverage and options for filling your prescription in order to get you started on therapy as quickly as possible.
Flexible and integrated resources for patient access and support:
XTANDI Patient Savings Program℠
Quick Start+℠ for XTANDI To enable rapid initiation of treatment, the Quick Start+™ program for XTANDI provides a one-time, 14-day gratis fill supply of XTANDI that requires a physician prescription. Quick Start+ is intended for new patients who have not received a coverage decision from their payer (for example, a benefit verification or prior authorization is pending) in time to start therapy in 10 business days. Quick Start+™ offers several benefits:
Astellas Access Program℠ Astellas is committed to supporting and maintaining access to medications for patients who are treated with an Astellas product.
The Astellas Access Program℠ for XTANDI is designed for patients who have no health insurance. This program provides free XTANDI to patients who qualify for enrollment based on insurance and household income status. Eligibility is determined on a patient-specific basis. XTANDI Support Solutions℠ can quickly determine whether a patient is eligible for enrollment.
If you need assistance with the Astellas eService site, XTANDI Support Solutions℠ or have any questions on coding, coverage, and reimbursement for Astellas products, please contact us between the hours of 9:00 AM and 8:00 PM ET Monday through Friday.
Contact Us XTANDI Support Solutions℠ Monday – Friday, 9:00 AM – 8:00 PM ET Phone: 1.855.8XTANDI (1.855.898.2634) Fax: 1.855.982.6341
Mailing Address Astellas Access Services℠ P.O. Box 13185 La Jolla, CA 92039
For Full Prescribing Information please see www.xtandi.com or contact Astellas Medical Communication at 1.800.961.0018.
XTANDI and Astellas are trademarks of Astellas Pharma Inc. XTANDI Support Solutions℠ is a component of Astellas Access Services℠.
Helping Patients Access the Care They Need
The AstraZeneca Access 360TM program provides personal support to help streamline access and reimbursement for select AstraZeneca medicines. Access 360 provides:
To learn more about the Access 360 program, please call 1-844-ASK-A360 (1-844-275-2360) Monday – Friday, 8 AM - 8 PM EST or visit www.MyAccess360.com.
CALQUENCE, FASLODEX, IMFINZI, IRESSA, LUMOXITI, LYNPARZA, and TAGRISSO are registered trademarks and AstraZeneca Access 360 is a trademark of the AstraZeneca group of companies. All other trademarks are property of their respective owners.
©2019 AstraZeneca. All rights reserved. US-29042 4/19
Patient Access, Reimbursement, and Co-Pay Support
Available Through
Bristol-Myers Squibb is committed to helping appropriate patients initiate and maintain access to our medications during the treatment journey. That's why we created BMS Access Support®, which offers benefit review, prior authorization assistance, and appeal process support, as well as an easy-to-initiate co-pay assistance process and information on financial support. The Oncology Co-pay Assistance Program assists with out-of-pocket co-payment or co-insurance requirements for eligible, commercially insured patients who have been prescribed certain Bristol-Myers Squibb oncology products.
For more information, visit BMS Access Support, or call BMS Access Support at 1.800.861.0048, 8 AM to 8 PM ET, Monday - Friday
Making patient support our priority by providing a broad range of access, reimbursement and clinical support solutions for patients who are prescribed GILOTRIF® (afatinib) tablets
Call Solutions Plus at 1-877-814-3915 from 8AM to 8PM EST or online at www.bisolutionsplus.com
www.celgenepatientsupport.com
A single source for access support
Celgene Patient Support® provides
Financial Assistance
Depending on a patient's insurance situation, there are programs and organizations that may help pay for the prescribed Celgene medication.
Insurance-Related Assistance
At the request of the patient, our Specialists are available to assist with each of the following steps in the insurance approval process for Celgene medications§
There are 3 simple ways to enroll your patient in Celgene Patient Support®:
*Other eligibility requirements and restrictions apply. Please see full Terms and Conditions on the Celgene Patient Support® website. †Financial and medical eligibility requirements vary by organization. ‡Patients must meet specified financial and eligibility requirements to qualify for assistance. §Celgene cannot provide insurance advice or make insurance decisions.
Helping Patients One at a Time
CoverOne® provides patient access and reimbursement support services to help patients gain appropriate access to BAVENCIO® (avelumab) in the United States.
We recognize that each patient's situation is different and are dedicated to helping BAVENCIO patients one at a time.
Phone: 844-8COVER1 (844-826-8371) Fax: 1-800-214-7295 Monday-Friday, 8:00am-8:00pm ET
CoverOne.com
The Eisai Assistance Program can provide information to patients and healthcare professionals about coverage for LENVIMA® and HALAVEN® and programs to help patients afford their medication. Depending on your financial situation and clinical status, resources may be available to help with patient's costs for LENVIMA® and HALAVEN®. The Eisai Assistance Program can also provide information about the LENVIMA® or HALAVEN® Patient Assistance Program which provides support to patients who need assistance paying for LENVIMA® or HALAVEN®. This program provides LENVIMA® or HALAVEN® at no cost to financially needy patients who meet program eligibility criteria.
We Focus on Access So You Can Focus on Health
If you are concerned about paying for your Genentech medicine, we are here to help. Whether you have health care coverage or not, we can help you by:
Visit Genentech-Access.com to learn more about these programs and how to get started. To speak live with one of our Specialists, call (866) 4ACCESS/(866) 422-2377.
Medicare and most private insurance carriers cover the Oncotype DX Breast Recurrence Score test for eligible patients with early-stage invasive breast cancer. In addition, Genomic Health created the Genomic Access Program (GAP) to help patients navigate the insurance and other payment options for Oncotype DX tests. Through GAP, Genomic Health takes every possible step to ensure testing is affordable, available, and accessible. To learn more about GAP, contact Customer Service by phone 866-ONCOTYPE (866-662-6897) or by email at customerservice@genomichealth.com.
IncyteCARES (Connecting to Access, Reimbursement, Education and Support) was established by Incyte to assist providers, patients, and caregivers through a single point of contact with reimbursement assistance, patient access, and distribution coordination for Jakafi® (ruxolitinib).
IncyteCARES assists healthcare professionals and eligible patients with product access through a suite of services, including:
You can contact IncyteCARES, for full program terms and eligibility, between 8 AM - 8 PM ET, by calling 1-855-4-JAKAFI (855-452-5234) or visit www.IncyteCARES.com.
Janssen CarePath
Janssen CarePath is your one source for resources focused on access, affordability, and treatment support for your patients. Our dedicated Care Coordinator team supports all the Janssen medications you prescribe. We can help make it easier for your patients and you to get the resources you both may need.
Access support to help navigate payer process.
Janssen CarePath helps verify insurance coverage for your patients and provides reimbursement information.
Our offerings include:
Affordability support to help your patients start and stay on treatment you prescribe
Support for patients using commercial or private insurance:
Support for patients using government insurance or patients without insurance coverage:
Treatment support to help your patients get informed and stay on prescribed treatment Janssen CarePath helps keep your patients informed about their condition and the importance of staying on treatment with:
Education tools
Adherence tools
Janssen CarePath Provider Portal
Janssen CarePath understands that navigating payer processes and finding cost support options may seem complicated at times. That's why we've created an enhanced Provider Portal experience. The Janssen CarePath Provider Portal at JanssenCarePathPortal.com gives healthcare providers and pharmacies 24-hour online access to:
Janssen CarePath Patient Account
Patients can create a Janssen CarePath Account at MyJanssenCarePath.com where they can:
Visit JanssenCarePath.com for more information about how to enroll your patients in Janssen CarePath or call your personally assigned Janssen CarePath Care Coordinator.
Content paid for and written by Johnson & Johnson Heath Care Systems Inc.
Contact: Janssen CarePath Care Coordinator 877.CarePath (877.227.3728) Monday-Friday, 8:00 AM - 8:00 PM ET Visit JanssenCarePath.com
* Independent co-pay assistance foundations have their own rules for eligibility. We have no control over these independent foundations and can only refer your patients to a foundation that supports their disease state. We do not endorse any particular foundation.
† The nurse program is limited to education for patients about their Janssen therapy, its administration, and/or their disease, and is not intended to provide medical advice, replace a treatment plan from the patient's doctor or nurse, or provide case management services.
Jazz Pharmaceuticals is committed to improving patient care through unique patient and physician programs and ongoing collaboration with patients, physicians, and advocacy groups.
Dedicated Reimbursement Specialists are available to assist patients with reimbursement for VYXEOS who have started treatment in either the inpatient or outpatient setting.
Reimbursement specialists can assist with the inpatient and outpatient setting with a number of things, including:
Call the Reimbursement Hotline at 1-855-5VYXEOS (1-855-589-9367) Available Monday through Friday, 9 AM to 8 PM ET
https://vyxeospro.com/support-materials/
Kite Konnect™ is committed to helping patients and healthcare teams throughout treatment.
For more information, visit KITEKONNECT.com or call 1-844-454-KITE.
LIBTAYO Surround™ helps eligible patients access LIBTAYO (cemiplimab-rwlc) and navigate the health insurance process
LIBTAYO Surround provides:
Patient support LIBTAYO Surround offers patient support that facilitates access to medication when patients need assistance with out-of-pocket costs, including:
Access and reimbursement support LIBTAYO Surround provides assistance with the reimbursement process, including:
Product support LIBTAYO Surround provides support with product ordering.
LIBTAYO Surround is committed to providing reimbursement and access support, as well as financial support for your eligible patients. Visit LIBTAYOhcp.com for more information about this program, or call 1-877-LIBTAYO (1-877-542-8296) Option 1, Monday–Friday, 8 AM–8 PM Eastern time.
The Lilly PatientOne program is committed to helping eligible patients access support programs for Lilly Oncology products they are prescribed. It aims to address both financial and coverage issues for qualified uninsured, underinsured, and insured patients who are prescribed a Lilly Oncology product. PatientOne strives to offer resources, ranging from benefits investigations to financial assistance and appeals information, that provide reliable and individualized treatment support for eligible patients.
Services offered by this program include:
Insurance expertise
Patient Assistance Program
Financial assistance
Reimbursement assistance for eligible Lilly Oncology products for an approved diagnosis
Denied claim appeals
For more information call 1-866-4PatOne (1-866-472-8663) Monday–Friday, 9AM–7PM ET or visit www.lillypatientone.com.
Enrollment AZEDRA Service Connection is a complimentary program and provides a simple enrollment process for patients.
Patient Access Specialists Our team of specialists will help you order AZEDRA and provide one-on-one phone assistance on matters such as out-of-pocket and reimbursement assistance to patients who are prescribed AZEDRA and their caregivers. Patient Access Specialists also connect patients to independent, third-party organizations for support*, including help finding transportation and lodging assistance.*†
1-844-AZEDRA1 https://azedra.com/support-program/
*Provided through independent third-party foundations (501(c)(3), tax-exempt nonprofit organizations). AZEDRA Service Connection Program has no control over independent, third-party programs and provides connections as a courtesy only.
†Based on program eligibility.
The Merck Access Program may help answer questions about:
Contact The Merck Access Program (MAP) by visiting merckaccessprogram.com or call 855-257-3932 Monday through Friday, 8AM to 8PM ET
Assistance. Access. Answers.
Novartis Oncology is committed to helping patients living with cancer receive the medicines they need. Patient Assistance Now Oncology (PANO) offers quick and easy access to information about the broad array of support and reimbursement programs available.
You can get information about our PANO support programs in 2 ways:
Support and resources for patients includes:
The Patient Access Network (PAN) Foundation is an independent, national 501 (c)(3) organization dedicated to helping federally and commercially insured people living with life-threatening, chronic and rare diseases with the out-of-pocket costs for their prescribed medications. Partnering with generous donors, healthcare providers and pharmacies, PAN provides the underinsured population access to the healthcare treatments they need to best manage their conditions and focus on improving their quality of life. Since its founding in 2004, PAN has provided nearly 1 million underinsured patients with over $3 billion in financial assistance, through over 60 disease-specific programs. For more information please visit http://www.PANFoundation.org or call 1.866.316.7263.
Puma Biotechnology offers the PumaPatientlynx™ program, which is designed to help patients get access to NERLYNX including:
Access and reimbursement support (i.e. insurance benefit investigation and prior authorization assistance)
Commercial Co-Pay Support
Financial support: referrals to charitable organizations for patients with financial needs
Supportive Care Voucher for products used with NERLYNX for side effect management
Quick Start
Patient Assistance Program:
Product Support
Contact Us Puma Patient Lynx 1-855-816-5421 Monday - Friday, 9AM to 8PM EST For Full Prescribing Information please see https://nerlynx.com/
TerSera SupportSource is here to assist in providing access to TerSera products. When you prescribe one of our treatments from TerSera (Zoladex® or Varubi®), there are reimbursement and coverage solutions to help remove barriers to treatment for your patients, including co-pay programs, hub/reimbursement information, and patient assistance programs.
Co-Pay questions: 844-864-3014 Insurance coverage/hub and Patient Assistance Programs questions: 855-686-8725
Teva Oncology: CORE (Comprehensive Oncology Reimbursement Expertise) offers reimbursement support for branded Teva Oncology products. Some of the options include benefit verification, prior authorization support and customer service through the claims and appeals process. CORE also provides referrals to the Teva Cares patient assistance program.
For more information or an introductory consult please call 1-888-587-3263 or visit www.TevaCore.com
Personalized assistance for IMBRUVICA® (ibrutinib) patients to help them:
Access Support We can help patients learn about access to IMBRUVICA® through:
Affordability Support Regardless of insurance type, we can help your patients understand their options
Nurse Call Support & Resources Your patients can talk to YOU&i™ nurses who can answer questions and provide information about IMBRUVICA® and their disease
Enrolling in the YOU&i™ Support Program is easy
Contact YOU&i™ Support 1.877.877.3536 Monday – Friday, 8:00 AM – 8:00 PM ET
Before prescribing IMBRUVICA® (ibrutinib), please see the full Prescribing Information available at www.IMBRUVICA.com.
Industry: Provide needed information on reimbursement programs and service available
For information on participating in the NCCN Reimbursement Resource Room or other support opportunities, please contact Jennifer Tredwell at tredwell@nccn.org.
About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Accessibility| Contact Us
3025 Chemical Road, Suite 100, Plymouth Meeting, PA 19462 • 215.690.0300 • Fax: 215.690.0280Copyright © 2019 National Comprehensive Cancer Network, All Rights Reserved